BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 19276231)

  • 1. Monokine induced by interferon gamma (IFNgamma) (CXCL9) and IFNgamma inducible T-cell alpha-chemoattractant (CXCL11) involvement in Graves' disease and ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists.
    Antonelli A; Ferrari SM; Fallahi P; Frascerra S; Santini E; Franceschini SS; Ferrannini E
    J Clin Endocrinol Metab; 2009 May; 94(5):1803-9. PubMed ID: 19276231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon-gamma-inducible alpha-chemokine CXCL10 involvement in Graves' ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma agonists.
    Antonelli A; Rotondi M; Ferrari SM; Fallahi P; Romagnani P; Franceschini SS; Serio M; Ferrannini E
    J Clin Endocrinol Metab; 2006 Feb; 91(2):614-20. PubMed ID: 16303841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peroxisome proliferator-activated receptor-α agonists modulate CXCL9 and CXCL11 chemokines in Graves' ophthalmopathy fibroblasts and preadipocytes.
    Antonelli A; Ferrari SM; Frascerra S; Ruffilli I; Gelmini S; Minuto M; Pupilli C; Miccoli P; Sellari-Franceschini S; Ferrannini E; Fallahi P
    Mol Cell Endocrinol; 2012 Feb; 349(2):255-61. PubMed ID: 22101320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytokines (interferon-γ and tumor necrosis factor-α)-induced nuclear factor-κB activation and chemokine (C-X-C motif) ligand 10 release in Graves disease and ophthalmopathy are modulated by pioglitazone.
    Antonelli A; Ferrari SM; Fallahi P; Piaggi S; Paolicchi A; Franceschini SS; Salvi M; Ferrannini E
    Metabolism; 2011 Feb; 60(2):277-83. PubMed ID: 20206950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CXCL9 and CXCL11 chemokines modulation by peroxisome proliferator-activated receptor-alpha agonists secretion in Graves' and normal thyrocytes.
    Antonelli A; Ferrari SM; Frascerra S; Pupilli C; Mancusi C; Metelli MR; Orlando C; Ferrannini E; Fallahi P
    J Clin Endocrinol Metab; 2010 Dec; 95(12):E413-20. PubMed ID: 20810571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. β (CCL2) and α (CXCL10) chemokine modulations by cytokines and peroxisome proliferator-activated receptor-α agonists in Graves' ophthalmopathy.
    Antonelli A; Ferrari SM; Frascerra S; Ruffilli I; Pupilli C; Bernini G; Sellari-Franceschini S; Gelmini S; Ferrannini E; Fallahi P
    J Endocrinol; 2012 May; 213(2):183-91. PubMed ID: 22378921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon-α, -β and -γ induce CXCL11 secretion in human thyrocytes: modulation by peroxisome proliferator-activated receptor γ agonists.
    Antonelli A; Ferrari SM; Mancusi C; Mazzi V; Pupilli C; Centanni M; Ferri C; Ferrannini E; Fallahi P
    Immunobiology; 2013 May; 218(5):690-5. PubMed ID: 22944249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential modulation of CXCL8 versus CXCL10, by cytokines, PPAR-gamma, or PPAR-alpha agonists, in primary cells from Graves' disease and ophthalmopathy.
    Ferrari SM; Ragusa F; Paparo SR; Nasini F; Nardi M; Franceschini SS; Fallahi P; Antonelli A
    Autoimmun Rev; 2019 Jul; 18(7):673-678. PubMed ID: 31059842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peroxisome proliferator-activated receptor α agonists modulate Th1 and Th2 chemokine secretion in normal thyrocytes and Graves' disease.
    Antonelli A; Ferrari SM; Frascerra S; Corrado A; Pupilli C; Bernini G; Benvenga S; Ferrannini E; Fallahi P
    Exp Cell Res; 2011 Jul; 317(11):1527-33. PubMed ID: 21565188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon-alpha, -beta and -gamma induce CXCL9 and CXCL10 secretion by human thyrocytes: modulation by peroxisome proliferator-activated receptor-gamma agonists.
    Antonelli A; Ferrari SM; Fallahi P; Ghiri E; Crescioli C; Romagnani P; Vitti P; Serio M; Ferrannini E
    Cytokine; 2010 Jun; 50(3):260-7. PubMed ID: 20299237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dysregulation of secretion of CXC alpha-chemokine CXCL10 in papillary thyroid cancer: modulation by peroxisome proliferator-activated receptor-gamma agonists.
    Antonelli A; Ferrari SM; Fallahi P; Frascerra S; Piaggi S; Gelmini S; Lupi C; Minuto M; Berti P; Benvenga S; Basolo F; Orlando C; Miccoli P
    Endocr Relat Cancer; 2009 Dec; 16(4):1299-311. PubMed ID: 19755523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [PPAR-γ agonist inhibits the expressions of chemokines induced by IFN-γ and TNF-α in renal tubular epithelial cells].
    Song Y; Lin Q; Zheng J; Zhu X; Yang S
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jul; 30(7):673-6. PubMed ID: 25001926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extra-ocular muscle cells from patients with Graves' ophthalmopathy secrete α (CXCL10) and β (CCL2) chemokines under the influence of cytokines that are modulated by PPARγ.
    Antonelli A; Ferrari SM; Corrado A; Franceschini SS; Gelmini S; Ferrannini E; Fallahi P
    Autoimmun Rev; 2014 Nov; 13(11):1160-6. PubMed ID: 25172242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The paramount role of cytokines and chemokines in papillary thyroid cancer: a review and experimental results.
    Fallahi P; Ferrari SM; Piaggi S; Luconi M; Cantini G; Gelmini S; Elia G; Ruffilli I; Antonelli A
    Immunol Res; 2018 Dec; 66(6):710-722. PubMed ID: 30617967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methimazole inhibits CXC chemokine ligand 10 secretion in human thyrocytes.
    Crescioli C; Cosmi L; Borgogni E; Santarlasci V; Gelmini S; Sottili M; Sarchielli E; Mazzinghi B; Francalanci M; Pezzatini A; Perigli G; Vannelli GB; Annunziato F; Serio M
    J Endocrinol; 2007 Oct; 195(1):145-55. PubMed ID: 17911406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon-γ and tumor necrosis factor-α sustain secretion of specific CXC chemokines in human thyrocytes: a first step toward a differentiation between autoimmune and tumor-related inflammation?
    Rotondi M; Coperchini F; Pignatti P; Sideri R; Groppelli G; Leporati P; La Manna L; Magri F; Mariotti S; Chiovato L
    J Clin Endocrinol Metab; 2013 Jan; 98(1):308-13. PubMed ID: 23118425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic induction of CXCL9 and CXCL11 by Toll-like receptor ligands and interferon-gamma in fibroblasts correlates with elevated levels of CXCR3 ligands in septic arthritis synovial fluids.
    Proost P; Verpoest S; Van de Borne K; Schutyser E; Struyf S; Put W; Ronsse I; Grillet B; Opdenakker G; Van Damme J
    J Leukoc Biol; 2004 May; 75(5):777-84. PubMed ID: 14996826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting chemokine (C-X-C motif) receptor 3 in thyroid autoimmunity.
    Fallahi P; Ferrari SM; Corrado A; Giuggioli D; Ferri C; Antonelli A
    Recent Pat Endocr Metab Immune Drug Discov; 2014; 8(2):95-101. PubMed ID: 24953644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolactin enhances interferon-gamma-induced production of CXC ligand 9 (CXCL9), CXCL10, and CXCL11 in human keratinocytes.
    Kanda N; Watanabe S
    Endocrinology; 2007 May; 148(5):2317-25. PubMed ID: 17255201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Expressions of CXCL9, CXCL10 and CXCL11 in renal tubular epithelial cells induced by IFN-γ].
    Lin Q; Song Y; Zhu X; Yang S; Zheng J
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 Feb; 29(2):137-40. PubMed ID: 23388331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.